Using nanoparticles to deliver epigenetic treatments for inflammatory bowel diseases
Nanoparticle-encapsulated Epigenetic Inhibitors for Treatment of Inflammatory Bowel Diseases
This study is exploring a new way to treat inflammatory bowel diseases like ulcerative colitis and Crohn's disease by using tiny particles to deliver special medicines that can help reduce inflammation in your colon, aiming for a treatment that works better and has fewer side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-11017829 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease by using nanoparticles to deliver bromodomain inhibitors. These inhibitors target a specific protein that plays a key role in inflammation, potentially leading to safer and more effective therapies. The approach involves encapsulating these inhibitors in nanoparticles to ensure they reach the areas of the colon that are inflamed. By utilizing both animal models and human patient samples, the research aims to create a targeted therapy that minimizes side effects while effectively reducing inflammation.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with ulcerative colitis or Crohn's disease, particularly those who have not responded well to existing treatments.
Not a fit: Patients with mild forms of inflammatory bowel disease or those who are not experiencing significant symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients suffering from inflammatory bowel diseases.
How similar studies have performed: Other research has shown promise in using targeted therapies for inflammatory conditions, but this specific approach using nanoparticle-encapsulated bromodomain inhibitors is relatively novel.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Tian, Bing — University of Texas Med Br Galveston
- Study coordinator: Tian, Bing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.